Embecta

Embecta Stock-Based Compensation

The Stock-Based Compensation (SBC) of Embecta (EMBC) as of Nov 21, 2026 is 31.60 M USD. In the previous year, Stock-Based Compensation (SBC) was 26.30 M USD — a change of 20.15% (higher).

Stock-Based Compensation

31.60 MUSD

YoY

20.15%

Last updated:

Stock-Based Compensation (SBC) of Embecta is 2025 31.60 M USD. Stock-Based Compensation (SBC) of Embecta was 2024 26.30 M USD. It decreases by 20.15% higher compared to the previous year.

The Embecta Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
12.00 M USD
Jan 1, 2020
12.70 M USD
Jan 1, 2021
12.80 M USD
Jan 1, 2022
18.70 M USD
Jan 1, 2023
21.50 M USD
Jan 1, 2024
26.30 M USD
Jan 1, 2025
31.60 M USD
The Embecta Stock-Based Compensation history
YEARStock-Based CompensationYoY
31.60 MUSD+20.15%
26.30 MUSD+22.33%
21.50 MUSD+14.97%
18.70 MUSD+46.09%
12.80 MUSD+0.79%
12.70 MUSD+5.83%
12.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Stock-Based Compensation (SBC) of Embecta is 31.60 M USD in 2025.

Stock-Based Compensation (SBC) of Embecta changed from 26.30 M USD to 31.60 M USD, representing a 20.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Embecta since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Embecta

All Key Metrics — Embecta